Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Short Interest Update

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) saw a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 19,100 shares, a decrease of 89.4% from the January 31st total of 180,500 shares. Based on an average daily trading volume, of 75,400 shares, the days-to-cover ratio is currently 0.3 days.

Medexus Pharmaceuticals Stock Up 2.1 %

Medexus Pharmaceuticals stock traded up $0.04 during trading hours on Friday, reaching $1.95. 6,917 shares of the stock were exchanged, compared to its average volume of 46,488. Medexus Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $3.88. The firm’s 50 day moving average is $2.48 and its 200 day moving average is $2.06.

Analyst Ratings Changes

Separately, Raymond James restated a “strong-buy” rating on shares of Medexus Pharmaceuticals in a research report on Monday, February 3rd.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.